The Challenge

Starting material sourcing, pricing, lead-time, and quality issues can have a significant impact on project timelines, downstream processes and finished product quality.

The Solution

We have developed robust and reliable alternative internal processing and external sourcing solutions for our customers starting materials to support clinical and commercial batch production. To provide assurance in supply, reduce cost and shorten lead-time, STA has the capacity to back-integrate both non-GMP and GMP starting material processes. To overcome starting material impurity issues, STA proactively identifies and synthesizes impurities to support analytical method development and fate tracking.

The Outcome

STA's offers secure manufacturing and supply solutions for our customers starting materials, advanced intermediates and API needs from preclinical to large-scale commercial manufacturing.

responsive icon Reactor Range

Flexible manufacturing assets consisting of 65 reactors ranging from 100 L to 5000 L, support projects from pre-clinical to pre-commercial launch campaigns.

committed icon Experience

Our FDA approved pilot plants are well equipped and experienced to scale up all types of reactions and support production of grams to hundreds of kilograms of advance intermediates and APIs.

managed icon 24/7 Operation

All of STA's manufacturing sites operate 24/7, with on-site process chemistry, engineering, quality and analytical support.

Innovate icon End-to-end

Fully integrated, end-to-end process R&D and API manufacturing capabilities, ensuring seamless transfer of know-how and scale, as programs advance from preclinical to commercial.